TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16219013
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times daily plus a diet providing an energy deficit of 1000 kcal/day
Study: 16219013
Drug: Both diet
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both diet treatment groups (500 kcal/day and 1000 kcal/day)
Study: 7552617
Drug: Intraoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiotherapy (IORT) with doses of 12.5-16.5 Gy
Study: 7552617
Drug: Adjuvant external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant external beam radiation (given to 23 of the 27 patients receiving IORT) with total doses ranging from 24 to 50 Gy
Study: 2843201
Drug: Enalapril 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 40 mg
Study: 2410720
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg (hypertension group)
Study: 2410720
Drug: Enalapril 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 40 mg (hypertension group)
Study: 27581208
Drug: initial triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: initial triple DMARD therapy (iTDT) with glucocorticoids (GCs) intramuscular
Study: 27581208
Drug: initial triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: initial triple DMARD therapy (iTDT) with an oral GC tapering scheme
Study: 27581208
Drug: initial MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: initial MTX monotherapy (iMM) with GCs
Study: 18306849
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive treatment modalities
Study: 12892607
Drug: Transparent posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transparent posterior capsule group
Study: 10975771
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose recombinant alpha-2a interferon (9 MU thrice weekly for 6 months, followed by 6 MU for another 6 months)
Study: 10975771
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose recombinant alpha-2a interferon (6 MU thrice weekly for 6 months, followed by 6 MU for another 6 months)
Study: 7847866
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine gel applied locally to painful skin area
Study: 7847866
Drug: Remote application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote application of lidocaine gel to mirror-image skin
Study: 2128266
Drug: Standard continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard continuous total parenteral nutrition (S-TPN)
Study: 2128266
Drug: Cyclic total
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic total parenteral nutrition (C-TPN)
Study: 7023166
Drug: Cimetidine (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1,200 mg daily)
Study: 28121466
Drug: 20-week trauma-sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-week trauma-sensitive yoga treatment
Study: 18956132
Drug: Alendronate (ALN,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (ALN, 70 mg/week) plus calcium (500 mg/daily) and vitamin D(3) (400 IU/daily)
Study: 18956132
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg/daily) and vitamin D(3) (400 IU/daily; Ca-Vit D group)
Study: 17050216
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing schedule (tablet phenytoin 100-400 mg/day OD or BD, tablet carbamazepine 200-800 mg BD, or both)
Study: 17050216
Drug: Chronotherapeutic dosing
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronotherapeutic dosing schedule (shift of daily dose to 20:00 h)
Study: 14656363
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) Turbohaler 1600 mcg daily
Study: 9137496
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg x 3
Study: 9137496
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg x 3 + Methylprednisolone 4 mg
Study: 9137496
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg x 3 + Methylprednisolone 4 mg + Ondansetron 8 mg x 3
Study: 2441175
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg acebutolol
Study: 2865028
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg betaxolol
Study: 23400742
Drug: etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etravirine 200 mg twice daily with fluconazole 200 mg daily
Study: 23400742
Drug: etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etravirine 200 mg twice daily with voriconazole 200 mg twice daily
Study: 18758284
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with open reduction and internal fixation using cannulated screw or Herbert screw.
Study: 18758284
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with open reduction and internal fixation using cannulated screw or Herbert screw.
Study: 23405792
Drug: Compound Xuanju
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Xuanju Capsule plus vitamin E
Study: 16227335
Drug: famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 20 mg
Study: 17502549
Drug: Modafinil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (400 mg/day)
Study: 15170874
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (0.5 mg/kg/day for 3 days, 0.25 mg/kg/day for 3 days, 0.1 mg/kg/day on day 7; total dose 2.35 mg/kg)
Study: 15170874
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (0.2 mg/kg/day for 3 days and 0.1 mg/kg/day for 4 days; total dose 1 mg/kg)
Study: 15170874
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between high-dose and low-dose dexamethasone
Study: 8092087
Drug: 6.5 mg
Normalized name: menthol 6.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg methionine.kg‐1.d‐1 plus 0 mg cystine.kg‐1.d‐1
Study: 8092087
Drug: 6.5 mg
Normalized name: menthol 6.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg methionine.kg‐1.d‐1 plus 5.2 mg cystine.kg‐1.d‐1
Study: 8092087
Drug: 6.5 mg
Normalized name: menthol 6.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg methionine.kg‐1.d‐1 plus 10.5 mg cystine.kg‐1.d‐1
Study: 8092087
Drug: 6.5 mg
Normalized name: menthol 6.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg methionine.kg‐1.d‐1 plus 20.9 mg cystine.kg‐1.d‐1
Study: 8092087
Drug: 13 mg
Normalized name: hemin 313 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 mg methionine.kg‐1.d‐1 without cystine
Study: 31880338
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC) swallowing therapy
Study: 23819675
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with sparse verbs
Study: 23819675
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with dense verbs
Study: 21365055
Drug: ITI (Institut
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITI (Institut Straumann) implants
Study: 21365055
Drug: SwissPlus (Zimmer
Approvals — FDA: no, EMA: no, PMDA: no
Description: SwissPlus (Zimmer Dental) implants
Study: 21365055
Drug: Astra (Astra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astra (Astra Tech) implants
Study: 19801020
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) 30,000 IU intravenously before tenecteplase treatment
Study: 9413414
Drug: Sertraline (50‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50‐200 mg daily)
Study: 9413414
Drug: Amitriptyline (50‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50‐150 mg daily)
Study: 3781184
Drug: Cisapride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (5 mg) intravenously 15 min before meal
Study: 3781184
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg) intravenously 15 min before meal
Study: 9506488
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg/kg)
Study: 20156348
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy using FloTrac/Vigileo device (GDT-group, n = 30)
Study: 16260965
Drug: Testosterone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (100 mg of testosterone enanthate)
Study: 14738260
Drug: Intravenous anti-D
Normalized name: anti-D (rh) immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anti-D
Study: 10096265
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral modafinil in the morning and 100 mg at midday
Study: 7781199
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 0.6 mg/kg IV as Solu‐Medrol
Study: 6104384
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion (500 micrograms/h) with active fungal lipase (150,000 E)
Study: 6104384
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion (500 micrograms/h) with placebo capsules
Study: 28349328
Drug: Doravirine 100
Normalized name: doravirine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine 100 mg alone
Study: 24528997
Drug: School-based inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based inhaled corticosteroid treatment
Study: 19121451
Drug: Nebivolol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol monotherapy
Study: 19121451
Drug: Nebivolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol plus diuretic
Study: 19121451
Drug: Nebivolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol plus calcium channel blocker
Study: 19121451
Drug: Nebivolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol plus other antihypertensive medication
Study: 15879354
Drug: Continuous methimazole
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous methimazole (MMI) treatment
Study: 2065721
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ketanserin
Study: 27889366
Drug: Intranasal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal lidocaine
Study: 27023009
Drug: Otelixizumab (anti-CD3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otelixizumab (anti-CD3 monoclonal antibody) administered subcutaneously
Study: 27023009
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid treatment
Study: 18204132
Drug: Extra-fine HFA
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-fine HFA beclomethasone dipropionate (HFA-BDP) 400 microg twice daily for 7 days followed by 200 microg twice daily for 4 days
Study: 15785378
Drug: Candesartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan treatment for 3 months
Study: 8585887
Drug: Single 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 30 mg dose of Centchroman (group I, n = 8)
Study: 8585887
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Centchroman twice a week for twelve weeks (group II, n = 5)
Study: 8585887
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing groups (group I and group II)
Study: 2162275
Drug: Vasoactive intestinal
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive intestinal peptide (IV infusion)
Study: 2162275
Drug: Peptide histidine
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peptide histidine valine (IV infusion)
Study: 2162275
Drug: Peptide histidine
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peptide histidine methionine (IV infusion)
Study: 2162275
Drug: Vasoactive intestinal
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive intestinal peptide (intra-arterial infusion)
Study: 2162275
Drug: Peptide histidine
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peptide histidine valine (intra-arterial infusion)
Study: 2162275
Drug: Vasoactive intestinal
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive intestinal peptide, peptide histidine methionine, peptide histidine valine (IV infusion)
Study: 375053
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with the same 4 drugs taken singly up to 182 days
Study: 22610853
Drug: Curcuminoids (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (1 g/day)
Study: 9777083
Drug: Caudal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal morphine 25 micrograms.kg‐1
Study: 9777083
Drug: Caudal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal morphine 50 micrograms.kg‐1
Study: 7889959
Drug: Cefprozil 500
Normalized name: cefprozil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil 500 mg q. 12 hours
Study: 7889959
Drug: Cefaclor 500
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 500 mg q. eight hours
Study: 7889959
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 500 mg q. 12 hours
Study: 7889959
Drug: Amoxicillin‐clavulanate 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanate 500 mg q. eight hours
Study: 29595510
Drug: ID93 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID93 + GLA-SE (10 μg ID93 + 2 μg GLA-SE)
Study: 29595510
Drug: ID93 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID93 + GLA-SE (2 μg ID93 + 2 μg GLA-SE)
Study: 29595510
Drug: ID93 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID93 + GLA-SE (10 μg ID93 + 5 μg GLA-SE)
Study: 18510625
Drug: 1-day oral
Normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-day oral sodium phosphate solution (NaP solution) (1 mL/kg/day, maximum 90 mL in two divided doses; regimen A)
Study: 18510625
Drug: 3-day magnesium
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day magnesium citrate (4 mL/kg/day x 3 days, maximum 237 mL, followed by an enema; regimen B)
Study: 18510625
Drug: 1-day oral
Normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-day oral sodium phosphate solution (NaP solution) (regimen A)
Study: 14632796
Drug: Evidence-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based treatment guidelines for pemphigus vulgaris
Study: 14719289
Drug: Compound Oldenlandis
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Oldenlandis Mixture
Study: 8615060
Drug: Calcipotriol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol treatment for 6 weeks
Study: 1091149
Drug: Short-term antibiotic
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term antibiotic prophylaxis regimen with 3 Gm. of cephaloridine in divided doses on the day of operation
Study: 1091149
Drug: Long-term antibiotic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antibiotic prophylaxis regimen with oral cephalexin postoperatively
Study: 19380134
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) abciximab administration
Study: 18389773
Drug: Special diet
Normalized name: Foods for special diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special diet consisting of 15 ml/day balsamic vinegar from apples and honey, seabuckthorn berry, rosemary, sage, and basil extracts, 150 g/day whole wheat bread with 2.5% VITAPAN, 15 ml/day grape seed extract rich in polyphenols (gr. 1)
Study: 15336619
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of alendronate daily + exercise (Al+Ex+)
Study: 15336619
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg alendronate daily (Al+Ex‐)
Study: 11519552
Drug: Barium suspension
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barium suspension with dynamic viscosity of 320 cPs (G1)
Study: 11519552
Drug: Barium suspension
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barium suspension with dynamic viscosity of 2500 cPs (G2)
Study: 11519552
Drug: Barium suspension
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barium suspension with dynamic viscosity of 3200 cPs (G3)
Study: 11519552
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) with standard barium suspension viscosity of 280 cPs
Study: 9781930
Drug: Perindopril, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril, 4 mg o.d. for 6 weeks
Study: 9781930
Drug: Losartan, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan, 50 mg o.d. for 6 weeks
Study: 7828343
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (5 micrograms/kg/min i.v.) for 83-296 hours
Study: 20837369
Drug: Aleglitazar (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleglitazar (600 μg/day)
Study: 16954961
Drug: Whey-predominant study
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey-predominant study formula (protein/energy ratio: 1.8 g/100 kcal)
Study: 16954961
Drug: Conventional casein-predominant
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional casein-predominant formula (protein/energy ratio: 2.6 g/100 kcal)
Study: 14707568
Drug: Neuromuscular blocking
Normalized name: Neuromuscular blocking agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blocking agents (NMBA)
Study: 14707568
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without NMBA (Control group)
Study: 7965783
Drug: Tandospirone citrate
Normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandospirone citrate (40, 80 and 160 mg)
Study: 7965783
Drug: Alprazolam (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.5, 1.0 and 2.0 mg)
Study: 2888691
Drug: Intraocular implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraocular implants after intracapsular and extracapsular extraction
Study: 2888691
Drug: Overall surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall surgery (both treatment modes)
Study: 29797670
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream (TD group)
Study: 29797670
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream (FTF group)
Study: 28823947
Drug: GSK2269557 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2269557 1000 μg
Study: 28823947
Drug: GSK2269557 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2269557 (various doses: 100, 200, 500, 700, 1000, 2000 μg)
Study: 17484511
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg DRSP/30 microg ethinyl estradiol (EE)
Study: 17484511
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg cyproterone acetate (CPA)/35 microg EE
Study: 9638309
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Tramal drops (100 mg tramadol-HCl)
Study: 9638309
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of tramadol (100 mg tramadol-HCl)
Study: 9638309
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Tramal drops
Study: 9638309
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of tramadol
Study: 7974587
Drug: CC method
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC method of measuring carotid stenosis
Study: 29951768
Drug: Acute cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute cocoa flavanols (530 mg CF, 100 mg epicatechin)
Study: 26808137
Drug: Low-dose/intensity regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose/intensity regimen of behavior modification (large-group parent training)
Study: 26808137
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of stimulant medication
Study: 22784349
Drug: Manasamitra Vataka
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manasamitra Vataka tablets (100 mg twice daily for 30 days)